Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.70 |
| ▸ | MEN1 | O00255 | 7/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.70 |
| ▸ | HPGD | P15428 | 7/20 | 0.70 |
| ▸ | TP53 | P04637 | 5/20 | 0.70 |
| ▸ | PKM | P14618 | 4/20 | 0.70 |
| ▸ | POLB | P06746 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 8/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.64 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.58 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.58 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6262977 | 0.91 | NPC1 (0.79) | NPC1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL31289469 | 0.88 | ALDH1A1 (0.58) | NPC1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL1662754 | 0.88 | MEN1 (0.84) | NPC1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL8768976 | 0.88 | HPSE (0.78) | NPC1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL419326 | 0.88 | NPC1 (0.71) | NPC1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL30533210 | 0.87 | MEN1 (0.73) | NPC1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL1655753 | 0.87 | MEN1 (0.73) | NPC1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL159873 | 0.86 | ALDH1A1 (0.74) | NPC1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL8769051 | 0.86 | MEN1 (0.71) | NPC1SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL30307784 | 0.86 | ALDH1A1 (0.74) | NPC1SMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024219864-A1 | NOVEL COMPOUND EXHIBITING SETDB1 INHIBITORY ACTIVITY, AND USE THEREOF | 주식회사 넷타겟 | 2024-10-24 | — | — | WO | disclosed |
| EP-2542076-B1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3251694-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit (Oxford) Limited (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-9622991-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9399651-B2 | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders | Merck, Sharp & Dohme Corp. (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150299227-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2015-10-22 | — | — | US | disclosed |
| US-9144557-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-09-10 | — | — | US | disclosed |
| US-9024032-B2 | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders | MERCK SHARP & DOHME CORP. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2488486-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012068406-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011109254-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| EP-2348855-A2 | SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION | Burnham Institute for Medical Research (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2010033643-A2 | SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT (OXFORD) LIMITED (GB) | 2009-03-19 | — | — | US | disclosed |
| EP-1986633-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Summit Corporation Plc (GB) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091106-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | HGF, EPOR, MPL | NPC1 4635/4885SMN1; SMN2 3850/4885ALDH1A1 3228/4885 |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | NPC1 2477/4885SMN1; SMN2 4/4885ALDH1A1 1203/4885 |
| US-20150299227-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | COMT, PNMT, TPMT | NPC1 2080/4885SMN1; SMN2 2558/4885ALDH1A1 186/4885 |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | NPC1 4555/4885SMN1; SMN2 941/4885ALDH1A1 2736/4885 |
| US-20090075938-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | NPC1 3637/4885SMN1; SMN2 9/4885ALDH1A1 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.